Physician profile
Mohamad Khair Khasawneh
NPI 1467403006
$998,239.12
in general payments reported to CMS, 2019-2025
56 companies · $115K in 2025
The $115K reported for 2025 was more than what 99% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $173K · 2020: $111K · 2021: $82K · 2022: $127K · 2023: $214K · 2024: $176K · 2025: $115K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $356K · Travel and Lodging: $69K · Consulting Fee: $65K · Food and Beverage: $13K · Honoraria: $2,060 · Education: $119.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $356,160.25 |
| Travel and Lodging | $68,736.57 |
| Consulting Fee | $64,803.09 |
| Food and Beverage | $12,803.31 |
| Honoraria | $2,060.00 |
| Education | $118.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $665,047.80 | 2019-2025 | Pemazyre, Jakafi, Zynyz |
| E.R. Squibb & Sons, L.L.C. | $131,245.37 | 2019-2025 | Opdivo, Augtyro, Opdualag |
| Amgen INC. | $79,153.92 | 2019-2024 | Kyprolis, Lumakras |
| Karyopharm Therapeutics INC. | $39,065.23 | 2020-2023 | Xpovio |
| Astrazeneca Pharmaceuticals Lp | $12,319.45 | 2019-2025 | Imfinzi, Truqap, Calquence |
| Merck Sharp & Dohme LLC | $11,066.76 | 2019-2025 | Keytruda, Welireg |
| Adc Therapeutics America, INC. | $10,740.16 | 2022-2023 | |
| Emd Serono, INC. | $8,689.68 | 2021-2024 | Bavencio |
| Abbvie INC. | $7,627.76 | 2021-2025 | |
| Immunogen, INC. | $6,891.06 | 2023-2024 | Elahere, Elahere |
| Jazz Pharmaceuticals INC. | $5,719.57 | 2019-2022 | |
| Sun Pharmaceutical Industries INC. | $5,545.70 | 2023 | |
| Pharmacosmos Therapeutics INC. | $4,720.72 | 2022-2023 | Monoferric |
| Beigene USA, INC. | $2,062.90 | 2021-2024 | Brukinsa |
| Astrazeneca Uk Limited | $1,505.84 | 2019 |
Show all 56 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohamad Khair Khasawneh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.